This move diversifies options for patients following the earlier approval of Eisai and Biogen's Leqembi in January. CVS faces ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

What is considered “high” blood pressure? How can you lower it? Dr. Muhammad Siyab Panhwar, a board-certified interventional cardiologist at Sanford Health of Minnesota, answers some of the most ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.